

[20] ()

(17 2)

1. () :

2. : 本末 本末

3. : 本末 5 本末 가 : ()

4. :

本末 本末

5. :

本末 本末

1) 本末

2) 12 本末 本末

3) 本末

4) 가 가

本末

5) 가

本末

6) 10 本末

210mm × 297mm(60g/m²)

. 가 .“

.

(20 , 가 ” ,
17 2) (1). 2~5

가

“ 1. () , 2. 가 .

(,), 3. ,

(5 , 가), 4.

(,) 5. 1 ‘ ’ 가

(,) ” 가 .

,

“

1) ‘ ,

() ” “ 1) ,

. 2)

12

(experiment) (therapeutic)

....”

가

가 ,

가 .

가 .

가 가

2)

가 . 2 가

(Code of Nuremberg) , (Institutional review board, IRB)
 (Declaration of Helsinki) ,
 .
 . Henry Beecher가 1966
 NEJM “ Ethics and Clinical research ” .²⁾
 22 ,
 , (typhoid fever) 3)
 (chloramphenicol) (Clinical trial) .
 .
 22.9% , 가 .
 7.97% . 1930
 Elixir sulfanilamide 100
 , .
 , 4 1 3 가 ,
 가 .
 , 3 1938 , (Food, Drug
 . Jewish Chronic Disease Hospital , the and Cosmetic act, FD & C act)
 Willowbrook . 1950
 .
³⁾, 1960 (Thalidomide)
 (Tuskegee syphilis study)가
 (The , 1990 International
 Belmont Report; 1979)가 . conference on Harmonization(ICH) .⁴⁾
 1953
 (NIH) 4)
 가 1966 . 26
 1970 (U.S. Food and 4
 Drug Administration, FDA)

(1).

2) Baruch A. Brody. The Ethics of Biomedical Research. An International Perspective. New York. Oxford, 1998: 35 - 54

3) (1955), (1968), 1950 (), 1960
 , 1970 . 植木 哲. 医療の 法律學. 有斐閣, 1998: 213 - 42

4) Shein - Chung Chow, Jen - Pei Liu. Design and Analysis of Clinical Trial. 2nd ed. New - Jersey. Wiley - Interscience, 2005: 1 - 34

‘ (Korea Good Clinical Practices, (Living donor)
 KGCP) ’ ICH - E6 (Cadaveric donor) .

가

5) , 2 “ 가 가 가 liv-
 ing anonymous donation .⁵⁾
 ()
 가 가

가

6) , 2) () 3
 가 . , , , ,
 , 16
 - (10 3). 16
 가 3 , 가 , ,
 4
 (4).

2 1 , ,
 1) (5)

5) Hoyer JA. Nondirected kidney donation and its consequences: personal experience of a transplant surgeon. Transplantation 2003; 76: 1264 - 65

가 2 1 (2).

, 16 2

16 가 3

(가) .

) (가 3 :

18 1). . (가) 2

가 1 가 2

3) , : 1 .

,가 (가) 1 (3)

. ,

(18 2 1)

(18 3).

가

(2). 4) 16 , ,가

, 가

가

가 .

가 가 .⁶⁾

(

11 1 1). ,가

2 (가 1 1)

1) 가 , 가 , 가

2 . 1970

가 가 1 .

, 가 ,

, 가

가 (1 . 1976

2). 가 가 가

6) . , 2000: 138

7) American College of Legal Medicine Textbook Committee. Legal Medicine, 6th ed. Philadelphia: Mosby, 2004: 312 - 3

가 가
. 가
, .⁸⁾
(Durable power of attorney)
가 가 ,
가 가 .
. .
(Advance Direc- 가 가
tives) (Oral) 가 ,
, ,
. 1990 (Patient Self
가 Determination Act)
Medicare Medicaid
(Clear and convincing evidence)
. .
. 1990
2) 가 가 .⁷⁾ 43 가
(Living will) 가 , (Bill of
Patient)
, 가 3)
가 가 .
가 . 50
가 가
가 가
(Value inventory) 가 가 .

8) Gregory. E. Pence. Classic Cases in Medical Ethics. 4ed. New York: McGraw Hill, 2004: 53

9) SUPPORT Principal Investigator, "A Controlled Trial to Improve Care for Seriously Ill Hospitalized Patients. The study to understand Prognoses and Preferences for Outcomes and Risks of Treatment(SUPPORT)." JAMA 1995; 274: 1591 - 8

가 , 가 가

,

9) , 가

가 .

가 가?

가 20 ,

가 가 가 . 3

가 가

3 , 가

가 가

10)

(Institutional review

board, IRB)

가

1. Baruch A. Brody. The Ethics of Biomedical Research. An Inter-

10) Uniform Health Care Decisions Act

- national Perspective. New York. Oxford, 1998: 35 - 54
2. 植木 哲. 医療の法律學. 有斐閣, 1998: 213 - 42
 3. Shein - Chung Chow, Jen - Pei Liu. Design and Aanalysis of Clinical Trial. 2nd ed. New - Jersey. Wiley - Interscience, 2005: 1 - 34
 4. Hoyer JA. Nondirected kidney donation and its consequences: personal experience of a transplant surgeon. Transplantation 2003; 76: 1264 - 65
 5. American College of Legal Medicine Textbook Committee. Legal Medicine. 6th ed. Philidelphia: Mosby, 2004: 312 - 3
 6. Gregory E. Pence. Classic Cases in Medical Ethics. 4ed. New York: Mcgraw Hill, 2004: 53
 7. SUPPORT Principal Investigator, "A Controlled Trial to Improve Care for Seriously Ill Hospitalized Patients. The study to understand Prognoses and Preferences for Outcpmes and Risks of Treatment(SUPPORT)." JAMA 1995; 274: 1591 - 8
 8. . , 2000: 138

8 ()

1. .
2. .
3. 2~3 가 .
4. 5 - 가 .
5. .
6. .
7. 16~17% .
8. 가 , , 가 .
9. 5 - .
10. .